PRTA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PRTA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Treasury stock is the portion of shares that a company keeps in their own treasury. Prothena's treasury stock for the quarter that ended in Sep. 2024 was $0.0 Mil.
Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.
The historical data trend for Prothena's Treasury Stock can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prothena Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Treasury Stock | Get a 7-Day Free Trial | - | - | - | - | - |
Prothena Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Treasury Stock | Get a 7-Day Free Trial | - | - | - | - | - |
The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.
Karin L Walker | officer: See Remarks | C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Brandon S. Smith | officer: Chief Operating Officer | C/O PROTHENA BIOSCIENCES INC., 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Carol D. Karp | officer: Chief Regulatory Officer | C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Michael J Malecek | officer: Chief Legal Officer | C/O PROTHENA BIOSCIENCES, INC., 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Hideki Garren | officer: Chief Medical Officer | C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Wagner M. Zago | officer: Chief Scientific Officer | C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Dennis J. Selkoe | director | 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Helen Susan Kim | director | 3832 BAY CENTER PLACE, HAYWARD CA 94545 |
Tran Nguyen | officer: Chief Financial Officer | C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Gene G. Kinney | officer: CSO & Head of R&D | C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Dunn William H. Jr. | director | C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Shane Cooke | director | TREASURY BUILDING LOWER GRAND CANAL ST., DUBLIN 2 L2 00000 |
Richard T Collier | director | |
Lars Ekman | director | C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
Paula K Cobb | director | NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453 |
From GuruFocus
By GuruFocus News • 11-07-2024
By Business Wire • 02-12-2024
By Business Wire • 11-12-2024
By GuruFocus Research • 02-28-2024
By Business Wire • 08-08-2024
By GuruFocus Research • 02-08-2024
By Business Wire • 11-05-2024
By GuruFocus Research • 05-28-2024
By GuruFocus Research • 02-08-2024
By GuruFocus News • 10-18-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.